Opaleye Management Inc. — 13F Holdings & Portfolio
CIK 1595855 · latest 13F-HR filed 2026-08-14
Opaleye Management Inc. manages $1.10B in 13F-reported U.S. long-equity assets across 58 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are LQDA (17.67%), ETON (9.38%), HROW (9.23%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 13 new positions, exited 9, added to 29, and trimmed 11.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
SUITE 2600
BOSTON, MA 02108
$1.10B
Long-equity book
58
Distinct positions
2026-06-30
Filed 2026-08-14
+13 / −9 / ↑29 / ↓11
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- LIQUIDIA CORPORATION$106.3M +119.7%
- DISC MEDICINE INC$35.6M +132.3%
- ETON PHARMACEUTICALS INC$32.9M +46.7%
- MEIRAGTX HLDGS PLC$29.6M +160.8%
- UROGEN PHARMA LTD$27.3M +106.1%
Top Trims
- RHYTHM PHARMACEUTICALS INC-$21.7M -61.5%
- SANUWAVE HEALTH INC-$13.9M -82.0%
- CG ONCOLOGY INC-$5.2M -80.3%
- ANNEXON INC-$3.1M -24.2%
- JADE BIOSCIENCES INC-$2.8M -46.4%
New Positions
- IMMIX BIOPHARMA INC$24.2M
- MONTE ROSA THERAPEUTICS INC$18.0M
- REPLIMUNE GROUP INC$15.3M
- VERASTEM INC$6.9M
- PHATHOM PHARMACEUTICALS INC$2.0M
Exited Positions
- PERSPECTIVE THERAPEUTICS INC$19.5M
- ASSERTIO HOLDINGS INC$5.1M
- SUTRO BIOPHARMA INC$4.7M
- TECTONIC THERAPEUTIC INC$3.8M
- RIGEL PHARMACEUTICALS INC$1.9M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | LIQUIDIA CORPORATION | LQDA | 53635D202 | $195.1M | 17.67% | 2,447,500 | SH |
| 2 | ETON PHARMACEUTICALS INC | ETON | 29772L108 | $103.5M | 9.38% | 2,860,000 | SH |
| 3 | HARROW INC | HROW | 415858109 | $101.9M | 9.23% | 2,400,000 | SH |
| 4 | DISC MEDICINE INC | IRON | 254604101 | $62.5M | 5.66% | 855,000 | SH |
| 5 | UROGEN PHARMA LTD | URGN | M96088105 | $53.0M | 4.80% | 1,439,996 | SH |
| 6 | APOGEE THERAPEUTICS INC | APGE | 03770N101 | $51.8M | 4.69% | 390,000 | SH |
| 7 | MEIRAGTX HLDGS PLC | MGTX | G59665102 | $48.0M | 4.34% | 3,550,000 | SH |
| 8 | SOL-GEL TECHNOLOGIES LTD | SLGL | M8694L137 | $37.1M | 3.36% | 500,000 | SH |
| 9 | REZOLUTE INC | RZLT | 76200L309 | $32.8M | 2.97% | 6,300,000 | SH |
| 10 | TG THERAPEUTICS INC | TGTX | 88322Q108 | $29.4M | 2.66% | 535,000 | SH |
| 11 | IMMIX BIOPHARMA INC | IMMX | 45258H106 | $24.2M | 2.19% | 2,345,000 | SH |
| 12 | CRESCENT BIOPHARMA INC. | CBIO | G2545C104 | $23.7M | 2.15% | 1,319,351 | SH |
| 13 | STOKE THERAPEUTICS INC | STOK | 86150R107 | $22.9M | 2.07% | 700,000 | SH |
| 14 | ALPHA COGNITION INC | ACOG | 02074J501 | $20.9M | 1.89% | 2,895,467 | SH |
| 15 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $20.3M | 1.84% | 500,000 | SH |
| 16 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $18.7M | 1.70% | 100,000 | SH |
| 17 | MONTE ROSA THERAPEUTICS INC | GLUE | 61225M102 | $18.0M | 1.63% | 745,000 | SH |
| 18 | ALUMIS INC | ALMS | 022307102 | $15.5M | 1.40% | 550,000 | SH |
| 19 | CODEXIS INC | CDXS | 192005106 | $15.3M | 1.39% | 6,785,000 | SH |
| 20 | REPLIMUNE GROUP INC | REPL | 76029N106 | $15.3M | 1.39% | 1,384,993 | SH |
| 21 | XOMA ROYALTY CORPORATION | XOMA | 98419J206 | $14.4M | 1.30% | 338,374 | SH |
| 22 | MBX BIOSCIENCES INC | MBX | 55287L101 | $14.4M | 1.30% | 260,000 | SH |
| 23 | RHYTHM PHARMACEUTICALS INC | RYTM | 76243J105 | $13.6M | 1.23% | 122,500 | SH |
| 24 | EDITAS MEDICINE INC | EDIT | 28106W103 | $12.5M | 1.13% | 3,861,930 | SH |
| 25 | PROTAGONIST THERAPEUTICS INC | PTGX | 74366E102 | $12.3M | 1.11% | 100,000 | SH |
| 26 | CABALETTA BIO INC | CABA | 12674W109 | $12.0M | 1.09% | 3,863,800 | SH |
| 27 | Q32 BIO INC | QTTB | 746964105 | $11.9M | 1.07% | 931,000 | SH |
| 28 | ANNEXON INC | ANNX | 03589W102 | $9.8M | 0.89% | 1,714,451 | SH |
| 29 | VERASTEM INC | VSTM | 92337C203 | $6.9M | 0.62% | 1,800,000 | SH |
| 30 | ZENTALIS PHARMACEUTICALS INC | ZNTL | 98943L107 | $6.9M | 0.62% | 1,412,656 | SH |
| 31 | RELMADA THERAPEUTICS INC | RLMD | 75955J402 | $6.5M | 0.59% | 935,000 | SH |
| 32 | OCULAR THERAPEUTIX INC | OCUL | 67576A100 | $5.9M | 0.53% | 600,000 | SH |
| 33 | TREVI THERAPEUTICS INC | TRVI | 89532M101 | $5.8M | 0.52% | 310,000 | SH |
| 34 | BRIDGEBIO ONCOLOGY THERAPEUT | BBOT | 107924102 | $5.3M | 0.48% | 700,000 | SH |
| 35 | LYELL IMMUNOPHARMA INC | LYEL | 55083R203 | $4.8M | 0.44% | 344,025 | SH |
| 36 | OPUS GENETICS INC | IRD | 67577R102 | $4.6M | 0.42% | 1,125,000 | SH |
| 37 | 4D MOLECULAR THERAPEUTICS IN | FDMT | 35104E100 | $4.4M | 0.40% | 334,437 | SH |
| 38 | INTELLIA THERAPEUTICS INC | NTLA | 45826J105 | $4.2M | 0.38% | 250,000 | SH |
| 39 | VOYAGER THERAPEUTICS INC | VYGR | 92915B106 | $4.1M | 0.38% | 1,185,000 | SH |
| 40 | BIODESIX INC | BDSX | 09075X207 | $4.1M | 0.37% | 180,000 | SH |
| 41 | ROCKET PHARMACEUTICALS INC | RCKT | 77313F106 | $3.4M | 0.31% | 1,000,000 | SH |
| 42 | JADE BIOSCIENCES INC | JBIO | 008064206 | $3.2M | 0.29% | 145,000 | SH |
| 43 | SANUWAVE HEALTH INC | SNWV | 80303D305 | $3.1M | 0.28% | 306,140 | SH |
| 44 | FORTRESS BIOTECH INC | FBIO | 34960Q307 | $2.7M | 0.25% | 890,000 | SH |
| 45 | JOURNEY MED CORP | DERM | 48115J109 | $2.5M | 0.22% | 350,000 | SH |
| 46 | PHATHOM PHARMACEUTICALS INC | PHAT | 71722W107 | $2.0M | 0.18% | 185,589 | SH |
| 47 | INHIBRX BIOSCIENCES INC | INBX | 45720N103 | $1.9M | 0.17% | 20,291 | SH |
| 48 | ENANTA PHARMACEUTICALS INC | ENTA | 29251M106 | $1.8M | 0.17% | 125,000 | SH |
| 49 | HEMAB THERAPEUTICS HLDGS INC | COAG | 423494103 | $1.8M | 0.16% | 47,652 | SH |
| 50 | FIRST TRACKS BIOTHERAPEUTICS | TRAX | 337185102 | $1.3M | 0.12% | 65,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $1.10B | 58 | 0001420506-26-001803 |
| 2026-03-31 | 2026-05-15 | $759.2M | 54 | 0001420506-26-001151 |
| 2025-12-31 | 2026-04-13 | $757.9M | 54 | 0001493152-26-016299 |
| 2025-12-31 | 2026-02-17 | $758.0M | 54 | 0001493152-26-007085 |